"Patients ask me if they are candidates for these new drugs (Ajovy and Aimovig). In my view, if someone has already tried at least two "standard" preventive medications yet is still significantly impacted by Migraine at least a few times per month (meaning disruption in their daily routine, ability to function, and reliability to work or care for others), that person is a candidate." Stephanie Nahas, MD

Ajovy™ Approved by FDA for Migraine Prevention in Adults

Ajovy™ (fremanezumab-vfrm), is the second monoclonal antibody has been approved by the FDA for prevention of Migraine in adults.
Ajovy Approved for Migraine

Leave a Reply

Your email address will not be published. Required fields are marked *